Zelniker TA, et al. - Researchers analyzed data from eight trials (n=77,242) to compare glucagon-like peptide 1 receptor agonists (GLP1-RA) with sodium-glucose cotransporter-2 inhibitors (SGLT2i) for preventive effects on major adverse cardiovascular events (MACE; a composite of myocardial infarction, stroke, and cardiovascular death) and adverse renal outcomes in patients with type 2 diabetes mellitus who did or did not have established atherosclerotic cardiovascular disease. Including GLP1-RA and SGLT2i cardiovascular outcomes trials, they conducted a systematic review and trial-level meta-analysis. The extent of atherosclerotic MACE attenuation in patients with established atherosclerotic cardiovascular disease was similar between GLP1-RA vs SGLT2i; however, SGLT2i had a greater marked influence on preventing hospitalization for heart failure and progression of kidney disease.